Parkinson's Disease and the Basal Ganglia: Lessons from the Laboratory and from Neurosurgery

During the last decade, a clearer understanding of the circuitry of the basal ganglia and their mode of operation has emerged. The basal ganglia are now viewed as parts of larger, segregated circuits that involve the thalamus and cerebral cortex. A pathophysiological model has been elaborated and tested in which Parkinsonian signs are viewed as resulting from increased activity of neurons in the "motor" portion of the internal pallidum, the major output nucleus of the basal ganglia, leading to increased inhibition of thalamocortical projection neurons and decreased activation of the precentral motor fields. Increased internal pallidal activity is thought to result from striatal dopamine loss, leading to decreased inhibition of the internal pallidum via a monosynaptic ("direct") striatopallidal pathway and to excessive excitatory glutamatergic drive via a polysynaptic ("indirect") striatopallidal pathway. Because current medical therapies for Parkinson's disease, aimed at systemically replacing dopamine, often lose their effectiveness after several years, with patients suffering from motor fluctuations and drug-induced dyski nesias, several new therapeutic strategies have been developed. In addition to the transplantation of dopaminergic tissue, other strategies attempt to reduce increased basal ganglia outflow directly by the placement of stereotactic lesions into the sensorimotor portion of the internal pallidum (pallidotomy) or by the chronic electric stimulation of the subthalamic nucleus. Preliminary results suggest that these new techniques may lead to significant improvement in Parkinsonian signs, motor fluctuations, and drug- induced dyskinesias. The Neuroscientist 1:236-244, 1995

[1]  L. Leksell,et al.  TREATMENT OF PARKINSONISM BY STEREOTACTIC THERMOLESIONS IN THE PALLIDAL REGION. A clinical evaluation of 81 cases. , 1960, Acta psychiatrica Scandinavica.

[2]  Professor Dr. med. Rolf Hassler,et al.  Stereotaxis in Parkinson Syndrome , 1979, Springer Berlin Heidelberg.

[3]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[4]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. D. Crutcher,et al.  Primate globus pallidus and subthalamic nucleus: functional organization. , 1985, Journal of neurophysiology.

[6]  D. Gash,et al.  Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. , 1987, Science.

[7]  J. Olney,et al.  Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. , 1987, European journal of pharmacology.

[8]  M. Delong,et al.  Altered Tonic Activity of Neurons in the Globus Pallidus and Subthalamic Nucleus in the Primate MPTP Model of Parkinsonism , 1987 .

[9]  L. Tremblay,et al.  Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys , 1988, Brain Research.

[10]  M. Price,et al.  Autopsy findings in a patient who had an adrenal‐to‐brain transplant for Parkinson's disease , 1989, Neurology.

[11]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[12]  M. Luquin,et al.  Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey , 1989, Neuropharmacology.

[13]  T. Klockgether,et al.  Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease , 1989, Trends in Neurosciences.

[14]  J. Bormann,et al.  Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. , 1989, European journal of pharmacology.

[15]  A. Nambu,et al.  Discharge patterns of pallidal neurons with input from various cortical areas during movement in the monkey , 1990, Brain Research.

[16]  M. Delong,et al.  Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.

[17]  S. Haber,et al.  Evidence for interconnections between the two segments of the globus pallidus in primates: a PHA-L anterograde tracing study , 1990, Brain Research.

[18]  H. Bergman,et al.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.

[19]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[20]  T. Klockgether,et al.  NMDA antagonists potentiate antiparkinsonian actions of L‐dopa in monoamine‐depleted rats , 1990, Annals of neurology.

[21]  G. E. Alexander,et al.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. , 1990, Progress in brain research.

[22]  L. Tremblay,et al.  Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.

[23]  J. Brotchie,et al.  Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate , 1991, Movement disorders : official journal of the Movement Disorder Society.

[24]  L. Tremblay,et al.  Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.

[25]  W T Thach,et al.  Basal ganglia motor control. III. Pallidal ablation: normal reaction time, muscle cocontraction, and slow movement. , 1991, Journal of neurophysiology.

[26]  R. Llinás,et al.  Electrophysiology of globus pallidus neurons: An in vitro study in guinea pig brain slices , 1991 .

[27]  T. Aziz,et al.  Lesion of the subthalamic nucleus for the alleviation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in the primate , 1991, Movement disorders : official journal of the Movement Disorder Society.

[28]  W. T. Thach,et al.  Basal ganglia motor control. I. Nonexclusive relation of pallidal discharge to five movement modes. , 1991, Journal of neurophysiology.

[29]  M. Hariz,et al.  Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. , 1992, Stereotactic and functional neurosurgery.

[30]  André Parent,et al.  Convergence of subthalamic and striatal efferents at pallidal level in primates: an anterograde double-labeling study with biocytin and PHA-L , 1992, Brain Research.

[31]  C. Marescaux,et al.  Contralateral disappearance of parkinsonian signs after subthalamic hematoma , 1992, Neurology.

[32]  M. Delong,et al.  Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding. , 1992, Journal of neurophysiology.

[33]  P. Strick,et al.  Multiple output channels in the basal ganglia. , 1993, Science.

[34]  A. Nambu,et al.  The distribution of the globus pallidus neurons with input from various cortical areas in the monkeys , 1993, Brain Research.

[35]  A L Benabid,et al.  [Effects of the stimulation of the subthalamic nucleus in Parkinson disease]. , 1993, Revue neurologique.

[36]  J L Vitek,et al.  Role of the thalamus in parkinsonian tremor: evidence from studies in patients and primate models. , 1993, Stereotactic and functional neurosurgery.

[37]  B Bioulac,et al.  Reversal of Rigidity and Improvement in Motor Performance by Subthalamic High‐frequency Stimulation in MPTP‐treated Monkeys , 1993, The European journal of neuroscience.

[38]  D. Brooks.  Functional imaging in relation to parkinsonian syndromes , 1993, Journal of the Neurological Sciences.

[39]  J. Ahlskog.  Cerebral transplantation for Parkinson's disease: current progress and future prospects. , 1993, Mayo Clinic proceedings.

[40]  T. Klockgether,et al.  Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist‐sensitive sites in the basal ganglia , 1993, Annals of neurology.

[41]  R Iansek,et al.  Motor functions of the basal ganglia , 1993, Psychological research.

[42]  J. Langston,et al.  Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. , 1993, Advances in neurology.

[43]  A light and electron microscopic analysis of the interconnections between the two pallidal segments and the subthalamic nucleus in the squirrel monkey , 1994 .

[44]  M R DeLong,et al.  The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. , 1994, Journal of neurophysiology.

[45]  H. Bergman,et al.  The primate subthalamic nucleus. I. Functional properties in intact animals. , 1994, Journal of neurophysiology.

[46]  J. A. Obeso,et al.  Restoration of thalamocortical activity after posteroventral pallidotomy in Parkinson's disease , 1994, The Lancet.

[47]  H. Bergman,et al.  The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. , 1994, Journal of neurophysiology.

[48]  R. Kurlan,et al.  Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.

[49]  A. Charara,et al.  Brainstem dopaminergic, cholinergic and serotoninergic afferents to the pallidum in the squirrel monkey , 1994, Brain Research.

[50]  C. Markham,et al.  Neural-Targeted Gene Therapy for Rodent and Primate Hemiparkinsonism , 1994, Experimental Neurology.